Molecularly targeted therapies for hepatocellular carcinoma: Sorafenib as a stepping stone

Digestive Diseases

Volumn 29, Issue 3, 2011, Pages 303-309

  Kim, Hwi Young ^a   Park, Joong Won ^a  

^a National Cancer Center   (South Korea)

Author keywords

Biomarker; Hepatocellular carcinoma; Molecularly targeted therapy; Sorafenib; Survival

Indexed keywords

ALPHA FETOPROTEIN; BEVACIZUMAB; BRIVANIB; CETUXIMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEMCITABINE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PLACEBO; PROTEIN KINASE B; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER PATIENT; CONFERENCE PAPER; DESQUAMATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEALTH CARE ORGANIZATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; ONCOGENE C KIT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PYRIDINES;

EID: 80051743574     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000327563     Document Type: Conference Paper

References (46)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
2. Sala M, Llovet JM, Bruix J: Considerations of the Barcelona Conference on the diagnosis and treatment of hepatocellular carcinoma (in Spanish). Gastroenterol Hepatol 2002; 25: 570-574. (Pubitemid 36336760)
3. Park KW, Park JW, Choi JI, et al: Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008; 23: 467-473. (Pubitemid 351342066)
4. Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002; 359: 1734-1739. (Pubitemid 34607087)
5. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. (Pubitemid 43112690)
6. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
7. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
8. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140.
9. Worns MA, Weinmann A, Schuchmann M, Galle PR: Systemic therapies in hepatocellular carcinoma. Dig Dis 2009; 27: 175-188.
10. Llovet JM, Di Bisceglie AM, Bruix J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
11. Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48(suppl 1):S20-S37.
12. KLCSG-NCC K: Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009; 15: 391-423.
13. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: Consensusbased clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72(suppl 1):2-15. (Pubitemid 350256660)
14. Siegel AB, Olsen SK, Magun A, Brown RS Jr: Sorafenib: Where do we go from here? Hepatology 2010; 52: 360-369.
15. Worns MA, Weinmann A, Pfingst K, et al: Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-495.
16. Pinter M, Sieghart W, Graziadei I, et al: Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14: 70-76.
17. Shim JH, Park JW, Choi JI, Park BJ, Kim CM: Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2009; 135: 617-625.
18. Okita K, Imanaka K, Chida N, et al: Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma treated after TACE. 2010 ASCO Gastrointestinal Cancers Symposium 2010, LBA128.
19. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300. (Pubitemid 46630787)
20. Colli A, Fraquelli M, Casazza G, et al: Accuracy of ultrasonography, spiral CT, magnetic resonance, andα-fetoprotein in diagnosing hepatocellular carcinoma: A systematic review. Am J Gastroenterol 2006; 101: 513-523. (Pubitemid 43340927)
21. Chan SL, Mo FK, Johnson PJ, et al: New utility of an old marker: Serialα-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27: 446-452.
22. Park JW, Finn RS, Kim JS, et al: Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011;17: 1973-1983.
23. Llovet JM, Pena C, Shan M, Lathia C, Bruix J: Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma randomized in the phase III SHARP trial. AASLD Annual Meeting Hepatology 2008, abstr 149.
24. Park JW, Kong SY, Lee NO, Kim CM, Kang SY, Nam BH: Cell-dependent response of BMS-582664 (brivanib) in hepatocellular carcinoma cells: Gene expression profiling study. Hepatology 2009; 50(suppl):1668A.
25. Moon WS, Rhyu KH, Kang MJ, et al: Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003; 16: 552-557. (Pubitemid 36718436)
26. Siegel AB, Cohen EI, Ocean A, et al: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998.
27. Zhu AX, Sahani DV, Duda DG, et al: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009; 27: 3027-3035.
28. Kanai F, Yoshida H, Tateishi R, et al: A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011; 67: 315-324.
29. Breuhahn K, Longerich T, Schirmacher P: Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25: 3787-3800. (Pubitemid 43980474)
30. Villanueva A, Chiang DY, Newell P, et al: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983.
31. Philip PA, Mahoney MR, Allmer C, et al: Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-6663. (Pubitemid 46190260)
32. Zhou J, Wang Z, Wu ZQ, et al: Sirolimusbased immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40: 3548-3553.
33. Casanovas O, Hicklin DJ, Bergers G, Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in latestage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309. (Pubitemid 41443415)
34. Loges S, Mazzone M, Hohensinner P, Carmeliet P: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 2009; 15: 167-170.
35. Paez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
36. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
37. Raoul J, Finn R, Kang Y, et al: An open-label phase II study of first-and second-line treatment with brivanib in patients with hepatocellular carcinoma. J Clin Oncol 2009; 27 (suppl):15s.
38. Thomas MB, Morris JS, Chadha R, et al: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-850.
39. Sergio A, Cristofori C, Cardin R, et al: Transcatheter arterial chemoembolization in hepatocellular carcinoma: The role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-921. (Pubitemid 351506379)
40. Xiong ZP, Yang SR, Liang ZY, et al: Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004; 3: 386-390.
41. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X: Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10: 2878-2882. (Pubitemid 39303010)
42. Shim JH, Park JW, Kim JH, et al: Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008; 99: 2037-2044.
43. Hoffmann K, Glimm H, Radeleff B, et al: Prospective, randomized, double-blind, multicenter, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation -HeiLivCa (ISRCTN24081794). BMC Cancer 2008; 8: 349.
44. Abou-Alfa G, Johnson P, Knox J, et al: Final results from a phase II, randomized, doubleblind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Gastrointestinal Cancers Symposium, Orlando, Fla, 2008
45. Zhu AX, Blaszkowsky LS, Ryan DP, et al: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898-1903. (Pubitemid 46638989)
46. Kim HY, Park JW, Nam BH, et al: Survival of patients with advanced hepatocellular carcinoma: Sorafenib versus other treatments. J Gastroenterol Hepatol DOI: 10.1111/ j.1440-1746.2011.06751.x.